RxDoctor Payments Data

Meghan Maloney

Adult Health · Darien, CTNPI 1821767872

Payments from drug & device makers

$709in general payments, 2019–2025

Across 25 payments — averaging $28.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$123
  • Amgen$88
  • Mannkind Corporation$73
  • Organon$70
  • Insulet Corporation$62
  • Sanofi-aventis U.S. LLC$45
  • plus $248 from 9 others

What the payments were for

  • Food & beverage$66694%
  • Education$436%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$709 in reported general payments places this provider in the 60th percentile of 418 adult health providers in Connecticut.

See all adult health providers in Connecticut

Medicare billing

Part B allowed, 2024
$21,720
Medicare patients
62
Services billed
411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide67$75,823
OzempicSemaglutide70$73,232
TrulicityDulaglutide46$59,433
JardianceEmpagliflozin47$58,943
JanuviaSitagliptin Phosphate12$14,315
TradjentaLinagliptin11$12,643
Tresiba Flextouch U-200Insulin Degludec14$8,042
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$5,894
Nano 2nd Gen Pen NeedlePen Needle, Diabetic47$4,011
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$3,914
Humalog Kwikpen U-100Insulin Lispro12$1,894
Metformin Hcl ErMetformin Hcl33$563
Metformin Hcl48$350
Glipizide ErGlipizide12$151

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$17$135,256113 claims
Novo NordiskOzempic$20$73,23270 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 418 adult health providers in Connecticut.

Other adult health in Darien

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →